Complex was evaluated on LNCaP/PC3 xenografts. High and stable PSMA-dependent tumor uptake (19.45 ± 2.14% ID/g at 2 h p.i). High kidney uptake followed by slow washout. Low nontarget organs uptake (<3% ID/g at 1 h p.i.) High target-to-non-target ratios: Tumor-to-blood 24.33 at 23 h p.i.Clinical translation: Yes, phase 1. The gene discussed is FOLH1; the disease is neoplasm.